Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an opportunity to ask questions after today's presentation. [Operator Instructions]
Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...
To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...
Pharmaceutical Technology on MSN18h
Syndax agrees funding with Royalty Pharma for Niktimvo US salesSyndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.
Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...
Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial ...
Stifel 2024 Healthcare Conference in New York, NY with a fireside chat on Monday, November 18, 2024, at 1:50 p.m. ET A live webcast of the fireside chats will be available in the Investor section of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback